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Cyclin-dependent kinases (CDKs) drive cell cycle 
progression and control transcriptional pro-
cesses. The dysregulation of multiple CDK family 
members occurs commonly in human cancer; in 
particular, the cyclin D-CDK4/6-retinoblastoma 
protein (RB)-iNK4 axis is universally disrupted, 
facilitating cancer cell proliferation and prompt-
ing long-standing interest in targeting CDK4/6 
as an anticancer strategy. Most agents that 
have been tested inhibit multiple cell cycle and 
transcriptional CDKs and have carried toxicity. 
However, several selective and potent inhibitors 
of CDK4/6 have recently entered clinical trial. 
PD0332991, the first to be developed, resulted 
from the introduction of a 2-aminopyridyl sub-
stituent at the C2-position of a pyrido(2,3-d)
pyrimidin-7-one backbone, affording exqui-
site selectivity toward CDK4/6.1 PD0332991 
arrests cells in G1 phase by blocking RB phos-
phorylation at CDK4/6-specfic sites and does 
not inhibit the growth of RB-deficient cells.2 
Phase i studies conducted in patients with 
advanced RB-expressing cancers demonstrated 
mild side effects and dose-limiting toxicities 
of neutropenia and thrombocytopenia, with 
prolonged stable disease in 25% of patients.3,4 
in cyclin D1-translocated mantle cell lymphoma, 
PD0332991 extinguished CDK4/6 activity in 
patients’ tumors, resulting in markedly reduced 
proliferation, and translating to more than 1 
year of stability or response in 5 of 17 cases.5
Two recent papers from the Knudsen 
laboratory make several important obser-
vations that will help guide the continued 
clinical development of CDK4/6 inhibitors. in 
the study by Dean et al., surgically resected 
patient breast tumors were grown on a tissue 
culture matrix in the presence or absence of 
PD0332991. Crucially, these cultures retained 
associated stromal components known to 
play important roles in cancer pathogenesis 
and therapeutic sensitivities, as well as key 
histological and molecular features of the pri-
mary tumor, including expression of eR, HeR2 
and Ki-67. Similar to results in breast cancer 
cell lines,6 the authors demonstrate that only 
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RB-positive tumors have growth inhibition in 
response to PD0332991, irrespective of eR or 
HeR2 status, while tumors lacking RB were 
completely resistant. This result underscores 
RB as the predominant target of CDK4/6 in 
breast cancer cells and the primary marker 
of drug response in primary patient-derived 
tumors. As expected, RB-negative tumors 
routinely demonstrated robust expression of 
p16iNK4A; however, p16iNK4A expression was not 
always a surrogate marker for RB loss, sup-
porting the importance of direct screening 
of tumors for RB expression to select patients 
appropriate for CDK4/6 inhibitor clinical trials.
in the second study, McClendon et 
al. investigated the efficacy of PD0332991 
in combination with doxorubicin in triple-
negative breast cancer cell lines. Again, RB 
functionality was paramount in determining 
response to either PD0332991 monotherapy 
or combination treatment. in RB-deficient 
cancer cells, CDK4/6 inhibition had no effect 
in either instance. However, in RB-expressing 
cancer cells, CDK4/6 inhibition and doxorubi-
cin provided a cooperative cytostatic effect, 
although doxorubicin-induced cytotoxicity 
was substantially reduced, assessed by mark-
ers for mitotic catastrophe and apoptosis. 
Additionally, despite cytostatic cooperativity, 
CDK4/6 inhibition maintained the viability of 
RB-proficient cells in the presence of doxo-
rubicin, which repopulated the culture after 
removal of drug. These results reflect previous 
data demonstrating that ectopic expression of 
p16iNK4A can protect cells from the lethal effects 
of DNA damaging and anti-mitotic chemo-
therapies.7 Similar results have been reported 
in MMTV-c-neu mice bearing RB-proficient 
HeR2-driven tumors, where PD0332991 com-
promised carboplatin-induced regressions,8 
suggesting that DNA-damaging treatments 
should not be combined concomitantly with 
CDK4/6 inhibition in RB-proficient tumors.
To combine CDK4/6 inhibition with cyto-
toxics, sequential treatment may be consid-
ered, in which CDK4/6 inhibition is followed by 
DNA damaging chemotherapy; cells relieved 
of G1 arrest may synchronously enter S phase, 
where they may be most susceptible to agents 
disrupting DNA synthesis. Release of myeloma 
cells from a prolonged PD0332991-mediated 
G1 block leads to S phase synchronization; 
interestingly, all scheduled gene expression 
is not completely restored (including factors 
critical to myeloma survival such as iRF4), fur-
ther favoring apoptotic responses to cytotoxic 
agents.9 Furthermore, in RB-deficient tumors, 
CDK4/6 inhibitors may be used to maximize 
the therapeutic window between transformed 
and non-transformed cells treated with che-
motherapy. in contrast to RB-deficient can-
cer cells, RB-proficient non-transformed cells 
arrested in G1 in response to PD0332991 are 
afforded protection from DNA damaging 
agents, thereby reducing associated toxicities, 
including bone marrow suppression.8
in summary, the current work provides 
evidence for RB expression as a determinant 
of response to CDK4/6 inhibition in primary 
tumors and highlights the complexity of com-
bining agents targeting the cell cycle machin-
ery with DNA damaging treatments.
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